2021 AUA Annual Meeting Highlights: Genitourinary Cancer

To better meet the educational needs of urologists and urologic healthcare providers, the AUA gathered from a variety of sources, including comprehensive literature searches and membership surveys to determine where gaps exist in the knowledge, proficiency, and practice in regards to genitourinary (GU) cancer. The needs assessment findings indicated that there is a need for educational education in managing patients with prostate cancer, muscle and non-muscle invasive bladder cancer and renal cell carcinoma.


The AUA Office of Education thanks the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support:

  • AstraZeneca
  • Bristol-Myers Squibb
  • Merck

Target Audience

  • Urologists
  • Urologists in training
  • Non-Physician providers involved in Urology

Learning Objectives

2021 Advanced Prostate Cancer Guideline Plenary

At the conclusion of the activity, participants will be able to:

  • Discuss the 2020 AUA/ASTRO/SUO Guideline for the management of advanced prostate cancer.

Prostate Cancer Update 2021

At the conclusion of the activity, participants will be able to:

  • Cite important new publications in this field during the past year.

  • Identify the relative strengths and weaknesses of the reports.

  • Appraise how new studies relate to the existing state-of-the-art in clinical practice.

  • Analyze whether they and their colleagues should consider changing their practice based on the new

AUA Guideline Amendment: Muscle Invasive Bladder Cancer/Non-Muscle Invasive Bladder Cancer

At the conclusion of the activity, participants will be able to:

  • Explain the 2020 amendments to the SUO/AUA Non-Muscle Invasive Bladder Cancer and Muscle Invasive Bladder Cancer Guidelines, including what to do if bacillus Calmette-Guérin (BCG) is unavailable.

First and Second Line Therapy in Advanced and Metastatic Bladder Cancer: A Changing Paradigm

At the conclusion of the activity, participants will be able to:

  • Analyze recent studies on first and second line therapies for treatment for advanced urothelial cancer.

Management of Non Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems 

At the conclusion of the activity, participants will be able to:

  • Implement current practice guidelines into the office setting.

  • Identify the best intravesical agent and duration of therapy for low, intermediate, and high risk settings and what to do during a BCG shortage.

  • Identify methods to treat significant toxicities from various intravesical therapies.

  • Define high risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease.

  • Discuss the scientific rationale for investigating immune oncology agents for BCG unresponsive disease and become familiar with current clinical trial designs

Advanced Renal Cell Carcinoma and Surgical Management of T1b and Hilar Renal Masses

At the conclusion of the activity, participants will be able to:

  • Manage bleeding complications of robotic partial nephrectomy

  • Describe the algorithm of immunotherapy treatment of advanced renal cell carcinoma

  • Minimize positive margin rates of robotic partial nephrectomy

Integrating Care for Oncology Patients: Establishing a Multidisciplinary Oncology Clinic with Advanced Therapeutics

At the conclusion of the activity, participants will be able to:

  • Describe the components of a multidisciplinary urologic cancer clinic and identify the best structure for the practice.

  • Deliver advanced therapeutics based on current and emerging best evidence including immunotherapy in urologic oncology patients.

  • Identify opportunities for shared care and team-based approaches of patients with urologic cancers including advanced prostate, bladder, and kidney cancer.

  • Demonstrate an understanding of advances in genomic testing and personalized medicine for urologic cancers.

  • Differentiate between new therapeutics that expand the treatment options for patients with urologic cancers and alter the definitions of cancer treatment.

Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider

At the conclusion of the activity, participants will be able to:

  • Describe the standard of care chemotherapy regimens for genitourinary malignancies.

  • Recall both historical and newer immunotherapy options in the treatment of genitourinary malignancies, including recently approved checkpoint inhibitors and antibody-drug conjugates.

  • Outline the mechanism of action of common chemotherapy and immunotherapy regimens for genitourinary malignancies.

  • Recognize and manage the adverse events related to these agents and the survivorship issues surrounding patients on systemic treatments for genitourinary malignancies.

  • List both completed and accruing clinical trials that are defining the paradigms of chemotherapy and immunotherapy use in genitourinary malignancies.

Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation
Course opens: 
Course expires: 

COI Review Work Group Disclosures

PDF icon COI Review Work Group Disclosures_2021_18.pdf

Author & Editor Disclosures

PDF icon Editor and Author Disclosures_AUA Highlights_GU.pdf

AUA Staff have nothing to disclose.

All relevant financial relationships have been mitigated.

Method of Participation

To claim CME credit/hours of participation, the learner must read the content, complete the posttest, passing with 80% accuracy and submit the evaluation and credit request form.

Estimated time to complete this activity: 1.25 hours
Release Date: December 2021
Expiration Date: December 31, 2022

Accreditation Statement

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments

Mitigation of Identified Conflict of Interest

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.

  • Attestation that clinical recommendations are evidence-based and free of commercial bias.

  • Introduction of a debate format (point-counterpoint)

  • Inclusion of moderated panel discussion with unbiased moderator

  • Publication of a parallel or rebuttal article for an article that is felt to be biased

  • Divestiture of the relationship by faculty

  • Recusal from controlling relevant aspects of planning

  • Selection of alternative faculty for specific topic

Off-label or Unapproved Use of Drugs or Devices 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


The opinions and recommendations express by faculty, authors and other experts whos input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association. 

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation
Please login or register to take this course.